📣 VC round data is live. Check it out!
- Public Comps
- Tecan Group
Tecan Group Valuation Multiples
Discover Tecan Group's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Insight Lifetech, Double Medical Technology, Carl Zeiss Meditec, Sinbon Electronics and more.
Tecan Group Overview
About Tecan Group
Tecan Group AG sells automated laboratory instruments and solutions for the diagnostics and life sciences research markets. The firm operates in two segments; The Life Sciences Business (end-customer business) segment supplies end users with automated workflow solutions directly. These solutions include laboratory instruments, software packages, application know-how, services, consumables, and spare parts, The partnering Business (OEM business) segment develops and manufactures OEM instruments and components that are distributed by partner companies under their names. A majority proportion of Tecan's revenue is generated in the Americas and Europe.
Founded
1980
HQ

Employees
3.9K
Website
Financials (LTM)
EV
$2B
Valuation Multiples
Start free trialTecan Group Financials
Tecan Group reported last 12-month revenue of $1B and EBITDA of $173M.
In the same LTM period, Tecan Group generated $388M in gross profit, $173M in EBITDA, and had net loss of ($54M).
Revenue (LTM)
Tecan Group P&L
In the most recent fiscal year, Tecan Group reported revenue of $1B and EBITDA of $172M.
Tecan Group is unprofitable as of last fiscal year, with gross margin of 35%, EBITDA margin of 15%, and net margin of (13%).
Financial data powered by Morningstar, Inc.
Tecan Group Stock Performance
Tecan Group has current market cap of $3B, and enterprise value of $2B.
Market Cap Evolution
Tecan Group's stock price is $199.46.
Tecan Group share price increased by 0.2% in the last 30 days, and decreased by 3.3% in the last year.
Tecan Group has an EPS (earnings per share) of $-11.10.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $3B | 0.0% | 0.2% | 16.8% | -3.3% | $-11.10 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTecan Group Valuation Multiples
Tecan Group trades at 2.1x EV/Revenue multiple, and 13.9x EV/EBITDA.
EV / Revenue (LTM)
Tecan Group Financial Valuation Multiples
As of June 4, 2026, Tecan Group has market cap of $3B and EV of $2B.
Tecan Group has a P/E ratio of (47.0x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Tecan Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Tecan Group Margins & Growth Rates
Tecan Group decreased revenue by 0% but EBITDA grew by 2% in the last fiscal year.
In the most recent fiscal year, Tecan Group reported gross margin of 35%, EBITDA margin of 15%, and net margin of (13%).
Tecan Group Margins
Tecan Group Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Tecan Group Operational KPIs
Tecan Group's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Tecan Group's Rule of 40 is 16% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Tecan Group's Rule of X is 16% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Tecan Group Competitors
Tecan Group competitors include Insight Lifetech, Double Medical Technology, Carl Zeiss Meditec, Sinbon Electronics, Ambu, TransMedics, Autobio Diagnostics, Dr. Lal PathLabs, BGI Genomics and Elekta.
Most Tecan Group public comparables operate across Medical Devices, Laboratory Services, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 29.2x | - | 131.6x | - | |||
| 5.9x | 5.6x | 16.4x | 13.9x | |||
| 1.1x | 1.1x | 6.5x | 7.4x | |||
| 2.3x | 2.3x | 15.9x | 17.6x | |||
| 2.8x | 2.7x | 14.6x | 14.7x | |||
| 4.6x | 4.2x | 17.0x | 17.4x | |||
| 4.1x | 4.0x | 10.1x | 10.3x | |||
| 10.1x | 8.7x | 31.5x | 30.9x | |||
This data is available for Pro users. Sign up to see all Tecan Group competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Tecan Group
Tecan Group has acquired 6 companies to date.
Last acquisition by Tecan Group was on December 1st 2025. Tecan Group acquired Wako Automation for undisclosed valuation.
Latest Acquisitions by Tecan Group
| Description | Wako Automation develops and markets proprietary automated workstations and systems for industrial applications. | Paramit Corporation is a Morgan Hill-headquartered contract manufacturer with facilities in California and Penang, Malaysia, serving medical device and instrument OEMs. Registered with the FDA for finished devices, it provides end-to-end services including design engineering, precision machining, assembly, testing, and packaging under ISO 13485 standards. Nearly one-fifth of its workforce consists of engineers specializing in electromechanical systems, optics, and fluidics, ensuring compliance through in-house QSIT-certified auditors and former FDA inspectors. | NuGEN Technologies is a genomics company offering sample preparation kits for next-generation sequencing. Its workflows amplify nucleic acids from limited, degraded, or formalin-fixed samples, enabling analysis on Illumina and other platforms. Headquartered in the United States, NuGEN supports research in oncology, reproductive health, and infectious diseases through robust, reproducible protocols. | SPEware Corp is a De Soto-headquartered manufacturer of solid phase extraction columns and instruments for labs in reference testing, biopharma, forensics, and toxicology. Its products feature micro-particle beds for purifying biological samples prior to LC-MS and GC analysis. SPEware supplies positive pressure processors, automated dispensers, and assay kits that reduce solvent use by 90 percent. The company serves clients like Quest Diagnostics and universities with high-throughput solutions for drug screening and metabolite extraction. | |
| HQ Country | |||||
| HQ City | - | San Jose, CA | San Francisco, CA | Los Angeles, CA | |
| Deal Date | 1 Dec 2025 | 23 Jun 2021 | 3 Sep 2018 | 31 Aug 2016 | |
| Valuation | undisclosed | $1B | $55M | $50M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Tecan Group acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Investments by Tecan Group
Tecan Group has invested in 2 companies to date.
Latest investment by Tecan Group was on January 8th 2021. Tecan Group invested in Labforward in their $6M Series B round (EV/Revenue multiple available to Pro users).
Latest Investments by Tecan Group
| Description | Labforward is a Berlin-headquartered provider of lab digitalization tools including the Labfolder electronic lab notebook and Laboperator IoT platform. These connect devices from Waters and Eppendorf, automate workflows, and integrate LIMS systems for life sciences and chemical R&D labs. Used by teams at Bayer and universities, the solutions enable remote equipment monitoring and data aggregation compliant with GxP standards. | Andrew Alliance is a Geneva-headquartered Swiss developer of robotic pipetting systems for life sciences laboratories. The Andrew platform automates multichannel liquid handling with one-touch labware recognition via camera vision and drag-and-drop software protocols. Andrew Assistant integrates with existing pipettes for precise volume control and error reduction. Founded in 2011, the company assembles instruments in Switzerland and has received funding from VentureKick and EUREKA EUROSTARS. Products support PCR preparation, serial dilutions, and high-throughput assays in research facilities worldwide. |
| HQ Country | ||
| HQ City | Berlin | Geneva |
| Deal Date | 8 Jan 2021 | 12 Jun 2018 |
| Round | Series B | Series C |
| Raised | $6M | $14M |
| Investors | 2mag-USA; Peppermint Venture Partners; Tecan Group | Inpeco; Omega Funds; Rancilio Cube Sicaf; Sam Eletr Trust; Tecan Group; Waters |
| Valuation | undisclosed | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Tecan Group investments and their VC round multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Tecan Group
| When was Tecan Group founded? | Tecan Group was founded in 1980. |
| Where is Tecan Group headquartered? | Tecan Group is headquartered in Switzerland. |
| How many employees does Tecan Group have? | As of today, Tecan Group has over 3K employees. |
| Is Tecan Group publicly listed? | Yes, Tecan Group is a public company listed on SIX Swiss Exchange. |
| What is the stock symbol of Tecan Group? | Tecan Group trades under TECN ticker. |
| When did Tecan Group go public? | Tecan Group went public in 2001. |
| Who are competitors of Tecan Group? | Tecan Group main competitors include Insight Lifetech, Double Medical Technology, Carl Zeiss Meditec, Sinbon Electronics, Ambu, TransMedics, Autobio Diagnostics, Dr. Lal PathLabs, BGI Genomics, Elekta. |
| What is the current market cap of Tecan Group? | Tecan Group's current market cap is $3B. |
| What is the current revenue of Tecan Group? | Tecan Group's last 12 months revenue is $1B. |
| What is the current revenue growth of Tecan Group? | Tecan Group revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Tecan Group? | Current revenue multiple of Tecan Group is 2.1x. |
| What is the current EBITDA of Tecan Group? | Tecan Group's last 12 months EBITDA is $173M. |
| What is Tecan Group's EBITDA margin? | Tecan Group's last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of Tecan Group? | Current EBITDA multiple of Tecan Group is 13.9x. |
| What is the current FCF of Tecan Group? | Tecan Group's last 12 months FCF is $120M. |
| What is Tecan Group's FCF margin? | Tecan Group's last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Tecan Group? | Current FCF multiple of Tecan Group is 20.1x. |
| How many companies Tecan Group has acquired to date? | As of June 2026, Tecan Group has acquired 6 companies. |
| What was the largest acquisition by Tecan Group? | $1B acquisition of Paramit Corporation on 23rd June 2021 was the largest M&A Tecan Group has done to date. |
| What companies Tecan Group acquired? | Tecan Group acquired Paramit Corporation, NuGEN Technologies, SPEware Corp, IBL International, Sias AG, and Wako Automation. |
| In how many companies Tecan Group has invested to date? | As of June 2026, Tecan Group has invested in 2 companies. |
| In what companies Tecan Group invested in? | Tecan Group invested in Andrew Alliance and Labforward. |
See public comps similar to Tecan Group
Lists including Tecan Group
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.


